Laser Therapy for Venous Leg Ulcers

Sponsor
Ahram Canadian University (Other)
Overall Status
Recruiting
CT.gov ID
NCT06135246
Collaborator
(none)
70
1
2
8.5
8.2

Study Details

Study Description

Brief Summary

This randomized controlled trial will evaluate the effects of high-intensity laser therapy on wound healing in patients with venous leg ulcers. Participants will be randomly assigned to receive either laser therapy plus standard care or standard care alone. The laser therapy will be administered 3 times per week for 8 weeks or until ulcer closure. The primary outcome is proportion of participants with complete ulcer closure.

Condition or Disease Intervention/Treatment Phase
  • Device: High Intensity Laser Therapy
  • Other: Standard Care
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
70 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Investigator)
Primary Purpose:
Treatment
Official Title:
Efficacy of High-Intensity Laser Therapy in the Management of Venous Leg Ulcers: A Randomized Controlled Trial
Anticipated Study Start Date :
Nov 16, 2023
Anticipated Primary Completion Date :
Aug 1, 2024
Anticipated Study Completion Date :
Aug 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Standard Care group

Participants will receive standard compression bandaging and wound care alone without high-intensity laser therapy. Bandaging will be applied weekly and wound care will be performed as per institutional protocols.

Other: Standard Care
Participants will receive standard compression bandaging and wound care as per institutional protocols, without any laser therapy. The compression bandaging protocol is based on recommendations from the American Venous Forum and American College of Phlebology guidelines (O'Donnell et al., 2014). Multi-layer compression bandages will be applied weekly by trained nurses, with layers including orthopedic padding, elastic bandages, and cohesive bandages. Bandages will be applied with high pressure at the ankle gradually decreasing up the leg, with an ankle pressure of approximately 40 mmHg (Mosti et al., 2015).

Experimental: High Intensity laser therapy + Standard care group

Participants will receive high-intensity laser therapy 3 times per week for 8 weeks or until ulcer closure in addition to standard care.

Device: High Intensity Laser Therapy
Participants will receive high-intensity laser therapy using an 810nm continuous wave diode laser (Multiwave locked System (MlS) provided by aSa). The laser applicator has a flat top hat beam profile with a spot size of 1cm2. The laser will be delivered in direct contact mode perpendicularly to the ulcer surface. Each 1cm2 area of the venous ulcer and a 1cm margin of periwound skin will be treated sequentially using a overlapping grid pattern to cover the entire ulcer area, with a 1 second exposure time per point. This results in a laser energy density of 4J/cm2 delivered to each point.
Other Names:
  • HILT
  • Other: Standard Care
    Participants will receive standard compression bandaging and wound care as per institutional protocols, without any laser therapy. The compression bandaging protocol is based on recommendations from the American Venous Forum and American College of Phlebology guidelines (O'Donnell et al., 2014). Multi-layer compression bandages will be applied weekly by trained nurses, with layers including orthopedic padding, elastic bandages, and cohesive bandages. Bandages will be applied with high pressure at the ankle gradually decreasing up the leg, with an ankle pressure of approximately 40 mmHg (Mosti et al., 2015).

    Outcome Measures

    Primary Outcome Measures

    1. Percent change in ulcer area from baseline to end of treatment [Baseline, 4 weeks, 8 weeks and 12 weeks after randomization]

      Ulcer area will be measured by tracing the wound perimeter on acetate paper and entering into image analysis software to calculate area in cm2. Percent change in ulcer area will be calculated as (area at end of treatment - area at baseline) / area at baseline x 100.

    Secondary Outcome Measures

    1. Rate of complete ulcer closure at end of treatment [Single time point at end of study at 12 weeks]

      Complete closure is defined as full re-epithelialization of the ulcer with no drainage. Assessed by clinical examination and tracing wound area as 0cm2. Reported as proportion of participants with complete closure.

    2. Time to complete ulcer closure [From baseline (week 0) until complete closure, up to 12 weeks.]

      Number of days from initial treatment until first point at which complete ulcer closure is achieved and maintained through end of treatment period.

    3. Changes in Quality of life [Change in total score on the Cardiff Wound Impact Schedule will be assessed from baseline (week 0), 4 weeks, 8 weeks and 12 weeks after randomization]

      The Cardiff Wound Impact Schedule is a condition-specific quality of life questionnaire designed for patients with chronic wounds. It contains 15 questions assessing physical symptoms and daily living. Each item is rated on a 4-point Likert scale from 1 (never) to 4 (all the time). Total score ranges from 15 to 60, with higher scores indicating poorer quality of life.

    4. Incidence of treatment-related adverse events [From initial treatment until 4 weeks after final treatment, up to 12 weeks total.]

      Adverse events will be graded per CTCAE v4.0. Number of participants experiencing each severity grade of adverse event related to study treatment will be reported.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Male or female patients aged 18 years up to 65 years.

    2. Presence of a venous leg ulcer, confirmed by clinical examination and Doppler ultrasound (venous reflux > 0.5 seconds).

    3. Ulcer size between 1 cm² and 20 cm² at screening.

    4. Ulcer duration of at least 4 weeks but not more than 12 months.

    5. Ankle-brachial index (ABI) ≥ 0.8, assessed by Doppler ultrasound.

    6. Willing and able to provide informed consent and comply with study procedures.

    Exclusion Criteria:
    1. Presence of an active infection in the ulcer, confirmed by clinical signs and positive culture results.

    2. Osteomyelitis, diagnosed by radiographs or magnetic resonance imaging (MRI).

    3. Patients with a history of uncontrolled diabetes, defined as HbA1c level > 10%.

    4. Current or planned use of systemic immunosuppressive drugs or corticosteroids during the study period.

    5. Pregnant or breastfeeding women.

    6. Patients with a history of malignancy or photosensitive skin disorders.

    7. Prior history of skin grafting or flap surgery in the affected area within the past 3 months.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Outpatient clinic of faculty of physical therapy, Ahram Canadian University Al Ḩayy Ath Thāmin Giza Egypt 3221405

    Sponsors and Collaborators

    • Ahram Canadian University

    Investigators

    • Study Chair: Amal Fawzy, Ph.D, Faculty of Physical Therapy, Ahram Canadian University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Mohamed Magdy ElMeligie, Director of Electromyography lab, Ahram Canadian University
    ClinicalTrials.gov Identifier:
    NCT06135246
    Other Study ID Numbers:
    • VLU-HILT-2023
    First Posted:
    Nov 18, 2023
    Last Update Posted:
    Nov 18, 2023
    Last Verified:
    Nov 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 18, 2023